While we developed canSAR to support cancer research and drug discovery, a key philosophy from the outset was to remain comprehensive in much of the data that we capture, going well beyond oncology. As such, canSAR contains the entire human proteome and all protein sequences in Uniprot (10); 3 million bioactive chemical structures and >8 million bioactivities, the entirety of PDB (26) etc. The reason for this strategy was 2-fold: (i) to ensure that cancer drug discovery benefits maximally from efforts in other therapeutic areas and (2) to support the discovery of novel cancer biology beyond what is already known. As a result, canSAR is already being used by drug discovery communities beyond cancer, especially to make use of the unique druggability and target assessments.
